Sweden
Research Article
Combination of Multiple Markers Predicts Prostate Cancer Outcome
Author(s): Maria A Svensson, Roopika Menon, Jessica Carlsson, Wenzel Vogel, Ove AndrénAndrén, Michael Nowak and Sven PernerMaria A Svensson, Roopika Menon, Jessica Carlsson, Wenzel Vogel, Ove AndrénAndrén, Michael Nowak and Sven Perner
Today we are facing a large problem of overtreatment in men with prostate cancer (PCa) due to the current lack of reliable prognostic biomarkers. Aberrations including ETS family gene rearrangements, phosphatase and tensin homolog (PTEN) deletions, enhancer of zeste homolog 2 (EZH2) overexpression and changes in the androgen receptor (AR) are commonly described in PCa and are believed to have an important role in progression of the disease. The aim of this study is to analyze if the protein expression of ERG, AR, PTEN and EZH2, and the deletion status of the PTEN, either alone or in combination can predict clinical outcome. Our cohort consists of 214 men that have undergone radical prostatectomy at the University Hospital of Örebro, Sweden between 1989-2005. Immunohistochemistry was used to detect AR, ERG, PTEN and EZH2 antigen and PTEN deletion was assessed using chromogenic in .. Read More»
DOI:
10.4172/2155-9929.1000213
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report